SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated announced today that the Company will present at the following investor conferences:
-- Baird's 2009 Health Care Conference in New York at 2:45 p.m. Eastern Time (ET) on September 9. -- Thomas Weisel Partners' Healthcare Conference 2009 in Boston at 9:45 a.m. ET on September 10. -- The 2009 Morgan Stanley Global Healthcare Unplugged Conference in New York at 8:35 a.m. ET on September 14. -- Think Equity's Sixth Annual Growth Conference in San Francisco at 1 p.m. ET on September 15.
These presentations are scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at http://www.gen-probe.com/. The webcasts will be available for 30 days following the events.
About Gen-Probe
Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,200 people. For more information, go to http://www.gen-probe.com/.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the period ended June 30, 2009, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Contact: Paula Izidoro Investor Relations 858-410-8904
Gen-Probe Incorporated
CONTACT: Paula Izidoro, Investor Relations of Gen-Probe Incorporated,
+1-858-410-8904
Web Site: http://www.gen-probe.com/
